Recombinant Rat CCL21/6Ckine Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

CCL21, also known as 6Ckine, TCA-4, SLC, Exodus-2, and A21, is a 12 kDa, homeostatic chemokine that plays an important role in the adaptive immune response and inflammation (1). Unlike other CC chemokines, rat CCL21 has a 36 amino acid (aa) C-terminal extension which mediates its attachment to carbohydrate structures and extracellular matrix components (2, 3). Mature rat CCL21 shares 66% and 84% aa sequence identity with human and mouse CCL21, respectively. Both human and mouse CCL21 signal through the chemokine receptor CCR7, while mouse (and likely rat) CCL21 can additionally signal through CXCR3 (4). CCL21 is constitutively presented on distal/terminal lymphatic vessels, high endothelial venules (HEV), and lymph node dendritic cells (DC) (5-7). Immobilized CCL21 promotes the docking of DC to lymphatic vessels and the retention of T cells by lymph node DC, resulting in T cell priming for activation (5, 6). DC interaction with the anchored chemokine can induce CCL21 cleavage and release of an 8 kDa fragment that lacks the C-terminal extension (7). During chronic inflammation or tissue damage, CCL21 is expressed by local vascular endothelial cells, macrophages, T cells, and neurons (8-11). In these settings, it promotes fibrosis, inflammatory cytokine production, and neuropathic pain (9-11). The soluble chemokine is elevated in the synovial fluid of rheumatoid arthritis patients, and in the serum of patients with coronary artery disease (8, 10). CCL21 has been shown to exert angiogenic or angiostatic effects (8, 12, 13). These effects, in combination with the ability of CCL21 to attract immune suppressor cells such as Treg and MDSC to a tumor site, can have either positive or negative effects on tumor progression (13, 14).

Array 7949-6C/CF

• CCL21/6Ckine Antibodies
• CCL21/6Ckine Lysate
• CCL21/6Ckine Proteins
• CCL21/6Ckine ELISAs
• CCL21/6Ckine Proteins and Enzymes